Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRAPK niraparib pharmacokinetics and toxicity in ovarian cancer
2020-005918-17Phase 4Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Hospices Civils de Lyon. Primary endpoint: Identification of factors associated with hematologic toxicity or nephrotoxicity. Started Feb 2021; status: active.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-005918-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005918-17.